Ezana M. Azene

Ezana M. Azene

Auto-generated profile, based on publicly available information

Ezana M. Azene

Gundersen Health System, La Crosse, Wisconsin

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2025 in Circulation
Verified
Journal Article
Open access
WJWissam A. Jaber
Wissam A. Jaber
CGCarin F. Gonsalves
Carin F. Gonsalves
SSStefan Stortecky
Stefan Stortecky
SHSamuel Horr
Samuel Horr
OPOrestis Pappas
Orestis Pappas
FIfor the PEERLESS Committees and Investigators*
for the PEERLESS Committees and Investigators*
BACKGROUND: There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism. METHODS: PEERLESS is a prospective, multicenter, randomized controlled trial that enrolled 550 patients with intermediate-risk pulmonary embolism with right ventricular dilatation and additional clinical risk factors randomized 1:1 to treatment with large-bore mechanical thrombectomy (LBMT) or catheter-directed thrombolysis (CDT). The primary end point was a hierarchal win ratio composite of the following (assessed at the sooner of hospital discharge or 7 days after the procedure): (1) all-cause mortality, (2) intracranial hemorrhage, (3) major bleeding, (4) clinical deterioration and/or escalation to bailout, and (5) postprocedural intensive care unit admission and length of stay. Assessments at the 24-hour visit included respiratory rate, modified Medical Research Council dyspnea score, New York Heart Association classification, right ventricle/left ventricle ratio reduction, and right ventricular function. End points through 30 days included total hospital stay, all-cause readmission, and all-cause mortality. RESULTS: The primary end point occurred significantly less frequently with LBMT compared with CDT (win ratio, 5.01 [95% CI, 3.68–6.97]; P <0.001). There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% versus 5.4%; P =0.04) with LBMT compared with CDT and less postprocedural intensive care unit use ( P 24 hours (19.3% versus 64.5%). There were no significant differences in mortality, intracranial hemorrhage, or major bleeding between strategies or in a secondary win ratio end point including the first 4 components (win ratio, 1.34 [95% CI, 0.78–2.35]; P =0.30). At the 24-hour visit, respiratory rate was lower for patients treated with LBMT (18.3±3.3 versus 20.1±5.1; P <0.001), and fewer had moderate to severe modified Medical Research Council dyspnea scores (13.5% versus 26.4%; P <0.001), New York Heart Association classifications (16.3% versus 27.4%; P =0.002), and right ventricular dysfunction (42.1% versus 57.9%; P =0.004). Right ventricle/left ventricle ratio reduction was similar (0.32±0.24 versus 0.30±0.26; P =0.55). Patients treated with LBMT had shorter total hospital stays (4.5±2.8 overnights versus 5.3±3.9 overnights; P =0.002) and fewer all-cause readmissions (3.2% versus 7.9%; P =0.03), whereas 30-day mortality was similar (0.4% versus 0.8%; P =0.62). CONCLUSIONS: PEERLESS met its primary end point in favor of LBMT compared with CDT in treatment of intermediate-risk pulmonary embolism. LBMT had lower rates of clinical deterioration and/or bailout and postprocedural intensive care unit use compared with CDT, with no difference in mortality or bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05111613.

11 November 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SVSuresh Vedantham
Suresh Vedantham
KDKush R. Desai
Kush R. Desai
IWIdo Weinberg
Ido Weinberg
WMWilliam Marston
William Marston
RWRonald Winokur
Ronald Winokur
KNKari Nelson
Kari Nelson

16 June 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SVSuresh Vedantham
Suresh Vedantham
IWIdo Weinberg
Ido Weinberg
KDKush R. Desai
Kush R. Desai
RWRonald Winokur
Ronald Winokur
KKKanti Pallav Kolli
Kanti Pallav Kolli
EAEzana Azene
Ezana Azene

1 August 2011 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
RWRodney D. Welling
Rodney D. Welling
EAEzana M. Azene
Ezana M. Azene
VKVivek Kalia
Vivek Kalia
KPKrit Pongpirul
Krit Pongpirul
ASAnna Starikovsky
Anna Starikovsky
DMDaniel J. Mollura
Daniel J. Mollura

20 June 2024 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
KGKristina A. Giles
Kristina A. Giles
AFAlik Farber
Alik Farber
MMMatthew T. Menard
Matthew T. Menard
MCMichael S. Conte
Michael S. Conte
BNBrian W. Nolan
Brian W. Nolan
RPRichard J. Powell
Richard J. Powell

15 February 2024 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
MBMohannad B. Bisharat
Mohannad B. Bisharat
EIEugene J. Ichinose
Eugene J. Ichinose
KVKalyan K. Veerina
Kalyan K. Veerina
VKVipul Khetarpaul
Vipul Khetarpaul
EAEzana M. Azene
Ezana M. Azene
DDDavid J. Dexter
David J. Dexter
Mechanical thrombectomy is a promising treatment option for deep vein thrombosis; however, long-term data are lacking. Here, we report for the first time the 1-year clinical outcomes from the completely enrolled ClotTriever Outcomes (CLOUT) registry evaluating mechanical thrombectomy with the ClotTriever System (Inari Medical). The CLOUT registry (NCT03575364) is a prospective, multicenter, single-arm study that enrolled 500 patients with proximal lower extremity deep vein thrombosis. Prespecified 1-year outcomes include Villalta score and corresponding postthrombotic syndrome (PTS) severity, duplex ultrasound findings of patency (defined as the presence of flow with normal or partial compressibility), Revised Venous Clinical Severity Score, and quality of life (QoL). In CLOUT, the median age was 61.9 years and 50.5% of patients were women. A total of 310 patients completed the 1-year visit. The 1-year PTS rate (Villalta score ≥ 5) was 19.3% and the moderate-to-severe PTS rate (Villalta score ≥ 10) was 8.8%. Median Villalta score decreased from 9.0 (IQR, 5.0-14.0) at baseline to 1.0 (IQR, 0.0-4.0) at 1 year (P < .0001). Similar rates of PTS and moderate-to-severe PTS were observed among limbs assessed at all study time points. Patency was observed in 94.2% of limbs. Median Revised Venous Clinical Severity Score was 6.0 (IQR, 3.0-9.0) at baseline and 3.0 (IQR, 1.0-4.0) at 1 year (P < .0001). Additionally, 90.4% of patients experienced improvements in QoL. One-year outcomes from the CLOUT registry demonstrate low PTS rates and preserved patency accompanied by improved symptom relief and QoL. Study follow-up through 2 years is ongoing.